250 related articles for article (PubMed ID: 31538326)
21. The Outcome of Hemolytic Disease of the Fetus and Newborn Caused by Anti-Rh17 Antibody: Analysis of Three Cases and Review of the Literature.
Dajak S; Ipavec N; Cuk M; Golubic Cepulic B; Mratinovic-Mikulandra J; Milardovic J; Stefanovic V
Transfus Med Hemother; 2020 Jun; 47(3):264-271. PubMed ID: 32595431
[TBL] [Abstract][Full Text] [Related]
22. Predicting Intrauterine Transfusion Interval and Perinatal Outcomes in Alloimmunized Pregnancies: Time-to-Event Survival Analysis.
Snelgrove JW; D'Souza R; Seaward PGR; Windrim R; Kelly EN; Ryan G
Fetal Diagn Ther; 2019; 46(6):425-432. PubMed ID: 31195389
[TBL] [Abstract][Full Text] [Related]
23. [Perinatal management and neurological outcome of newborns hospitalized with Rhesus hemolytic disease].
Gobalakichenane P; Lardennois C; Galène-Gromez S; Brossard V; Marpeau L; Verspyck E; Marret S;
Gynecol Obstet Fertil; 2008 Oct; 36(10):984-90. PubMed ID: 18804397
[TBL] [Abstract][Full Text] [Related]
24. [Significance of alloantibodies other than anti-D hemolytic disease of the fetus and newborn (HDF/N)].
Lenkiewicz B; Zupańska B
Ginekol Pol; 2003 Jan; 74(1):48-54. PubMed ID: 12715437
[TBL] [Abstract][Full Text] [Related]
25. Intravenous immune globulin in the management of severe Rh D hemolytic disease.
Porter TF; Silver RM; Jackson GM; Branch DW; Scott JR
Obstet Gynecol Surv; 1997 Mar; 52(3):193-7. PubMed ID: 9061721
[TBL] [Abstract][Full Text] [Related]
26. Outcome predictors for maternal red blood cell alloimmunisation with anti-K and anti-D managed with intrauterine blood transfusion.
Vlachodimitropoulou E; Garbowski M; Anne Solomon S; Abbasi N; Seaward G; Windrim R; Keunen J; Kelly E; Van Mieghem T; Shehata N; Ryan G
Br J Haematol; 2022 Feb; 196(4):1096-1104. PubMed ID: 34862601
[TBL] [Abstract][Full Text] [Related]
27. A case of fatal hemolytic disease of the newborn associated with-D-/-D-phenotype.
Han KS; Kim HC; Han KS; Shim WS
Am J Perinatol; 1997 Sep; 14(8):495-7. PubMed ID: 9376014
[TBL] [Abstract][Full Text] [Related]
28. Exchange transfusion of least incompatible blood for severe hemolytic disease of the newborn due to anti-Rh17.
Li BJ; Jiang YJ; Yuan F; Ye HX
Transfus Med; 2010 Feb; 20(1):66-9. PubMed ID: 19725902
[TBL] [Abstract][Full Text] [Related]
29. The role of immunoglobulins in neonatal Rhesus haemolytic disease.
Greenough A
BioDrugs; 2001; 15(8):533-41. PubMed ID: 11543694
[TBL] [Abstract][Full Text] [Related]
30. A successful delivery of an extremely immature infant in Rh incompatibility after plasma exchange.
Hayashi K; Kondo T; Nosaka K; Yamanaka S; Hamada H; Horiuchi T
Keio J Med; 1989 Jun; 38(2):184-91. PubMed ID: 2506392
[TBL] [Abstract][Full Text] [Related]
31. Hemolytic disease of the fetus and newborn owing to anti-U, successfully treated with repeated intrauterine transfusions.
Strindberg J; Lundahl J; Ajne G
Immunohematology; 2013; 29(2):51-4. PubMed ID: 24094236
[TBL] [Abstract][Full Text] [Related]
32. The management of hemolytic disease in the fetus and newborn.
Bowman J
Semin Perinatol; 1997 Feb; 21(1):39-44. PubMed ID: 9190032
[TBL] [Abstract][Full Text] [Related]
33. Effect of Anti-D titers in RhD-negative pregnant women on fetuses and newborns: A retrospective study.
Tang TH; Guo CY; Li XY; Hu YX; Liu WK; Yu MX
Pediatr Neonatol; 2024 May; 65(3):288-292. PubMed ID: 37957047
[TBL] [Abstract][Full Text] [Related]
34. Hemolytic disease of the fetus and newborn caused by anti-Hr
Sarihi R; Ahmadnejad M; Mohammadi S; Eshghi P; Herfat F; Jolharnejad S; Oodi A
Transfus Apher Sci; 2021 Feb; 60(1):102913. PubMed ID: 32943324
[TBL] [Abstract][Full Text] [Related]
35. Intravenous immunoglobulin in the management of severe early onset red blood cell alloimmunisation.
Vlachodimitropoulou E; Lo TK; Bambao C; Denomme G; Seaward GR; Windrim R; Tessier F; Kelly E; Van Mieghem T; Ryan G
Br J Haematol; 2023 Jan; 200(1):100-106. PubMed ID: 36100813
[TBL] [Abstract][Full Text] [Related]
36. Plasma exchange and high-dose i.v. immunoglobulin in the treatment of severe rhesus hemolytic disease.
Berlin G; Selbing A; Gottvall T
Prog Clin Biol Res; 1990; 337():337-40. PubMed ID: 2112753
[No Abstract] [Full Text] [Related]
37. Relationship between obstetric history and Rh(D) alloimmunization severity.
Lobato G; Soncini CS
Arch Gynecol Obstet; 2008 Mar; 277(3):245-8. PubMed ID: 17763861
[TBL] [Abstract][Full Text] [Related]
38. Management and clinical consequences of red blood cell antibodies in pregnancy: A population-based cohort study.
Liu S; Ajne G; Wikman A; Lindqvist C; Reilly M; Tiblad E
Acta Obstet Gynecol Scand; 2021 Dec; 100(12):2216-2225. PubMed ID: 34476807
[TBL] [Abstract][Full Text] [Related]
39. Long-term neurodevelopmental outcome after intrauterine transfusion for the treatment of fetal hemolytic disease.
Hudon L; Moise KJ; Hegemier SE; Hill RM; Moise AA; Smith EO; Carpenter RJ
Am J Obstet Gynecol; 1998 Oct; 179(4):858-63. PubMed ID: 9790359
[TBL] [Abstract][Full Text] [Related]
40. Neonatal outcome after fetal anemia managed by intrauterine transfusion.
Garabedian C; Rakza T; Thomas D; Wibaut B; Vaast P; Subtil D; Houfflin-Debarge V
Eur J Pediatr; 2015 Nov; 174(11):1535-9. PubMed ID: 26032762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
